Treatment for relapsed acute leukaemia has a high-risk of treatment-related morbidity and mortality, particularly infectious complications. HSCT, novel agents and cell therapies used in refractory leukaemia may also be associated with significant treatment-related side effects. Families and patients from regional centres may need to move closer to the specialist cancer service due to

the toxicity of therapy. Support of the patient and family, including access to information, should be managed under the family-centred care principles discussed in Principle 4 ‘Supportive care’.